Sanofi has kicked off 2026 with a strong first-quarter performance, reporting revenues of over €10.5 billion, a 13.6% increase at constant exchange rates. These healthy financials set a positive stage for incoming CEO Belén Garijo, who is scheduled to officially succeed Paul Hudson on April 29.
The primary driver of this financial uplift remains the immunology blockbuster Dupixent, which saw a 30.8% surge in sales to €4.2 billion. The company’s vaccine portfolio also received a boost from the Heplisav-B hepatitis B range, following the strategic acquisition of Dynavax. Notably, Sanofi is successfully diversifying its revenue streams; a group of recently launched products, including the haemophilia therapy Altuviiio and the diabetes treatment Tzield, grew by nearly 50% to reach €1.1 billion, signaling a diminishing reliance on its lead asset.
Under interim CEO Olivier Charmeil, the group secured five regulatory approvals and reported significant progress in its clinical pipeline. Looking ahead, Sanofi maintains its 2026 guidance for high single-digit sales growth, with several anticipated approvals later this year for multiple sclerosis, multiple myeloma, and a new rabies vaccine. The transition to Garijo’s leadership comes at a time when the company is focused on delivering profitable growth amid a shifting R&D landscape.
Source: https://pharmaphorum.com/news/sanofi-welcomes-incoming-ceo-sales-lift